“For younger firms with small teams and limited business expertise, this poses an additional challenge. Engaging an established IR and capital markets advisory firm with experience in biotech fundraising can help biotech companies reach their full potential.”
Unfortunately Management don’t seem to get it..Our Science is in the Big League but Anp still thinks we can get finance from an exhausted Australian Biotech market where Anp has not realised we need Professional full time people
1) more scientists to help with more indications
2) Experienced US Biotech hot shots wit financial market connections
3)CG, GP, Etc are all part time. We need full time professionals working for ANP in the US.
Unless we implement these changes ASAP
Our Science will be worthless.
“For younger firms with small teams and limited business...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $92.40M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $99.43K | 979.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 23629 | 1 |
View Market Depth
| Last trade - 15.33pm 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |